enGene Therapeutics (ENGN) EBT (2023 - 2026)
enGene Therapeutics (ENGN) posted quarterly EBT of -$30.2 million for Q2 2026, down 18.19% year-over-year from -$36.9 million in Q2 2025, and down 1.6% quarter-over-quarter from -$29.8 million in Q1 2026.
enGene Therapeutics (ENGN) EBT (2023 - 2026) Analysis & Trends
enGene Therapeutics (ENGN) has reported EBT for 4 consecutive years, with -$30.2 million the latest figure, recorded in Q2 2026.
- In Q2 2026, EBT fell 18.19% year-over-year to -$30.2 million; the TTM figure through Apr 2026 stood at -$23.4 million (up 70.64% YoY), while the FY2025 annual figure was -$13.6 million, up 75.39% from the prior year.
- EBT eased to -$30.2 million in Q2 2026 per ENGN's latest filing, from -$29.8 million in the prior quarter.
- Across five years, EBT topped out at $65.4 million in Q4 2025 and bottomed at -$82.5 million in Q4 2023.
- Historically, EBT has averaged -$16.3 million across 4 years, with a median of -$15.1 million in 2024.
- Annual changes were most pronounced in 2024 — EBT tumbled 200.36% — and 2025, when it jumped 527.68%.
- enGene Therapeutics' EBT stood at -$82.5 million in 2023, then jumped by 81.47% to -$15.3 million in 2024, then surged by 527.68% to $65.4 million in 2025, then sank by 146.25% to -$30.2 million in 2026.
- Business Quant data shows ENGN's EBT at -$30.2 million in Q2 2026, -$29.8 million in Q1 2026, and $65.4 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.82 Bn | 131.97 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 86.69 Bn | 78.70 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 65.23 Bn | 60.05 Bn | 1.37 Bn | 541.00 Mn |
| 4 | Moderna | 60.16 Bn | 55.02 Bn | 52.00 Mn | -767.00 Mn |
| 5 | BeOne Medicines | 42.16 Bn | 37.07 Bn | 1.53 Bn | 312.46 Mn |
| 6 | Alnylam Pharmaceuticals | 31.86 Bn | 28.55 Bn | 992.69 Mn | 177.81 Mn |
| 7 | BioNTech SE | 28.24 Bn | 9.85 Bn | 668.28 Mn | -264.70 Mn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | -11.37 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | 81.49 Mn |
| 10 | enGene Therapeutics | 124.46 Mn | 124.46 Mn | - | -30.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | -30.23 Mn |
| Jan 31, 2026 | -29.75 Mn |
| Oct 31, 2025 | 65.35 Mn |
| Jul 31, 2025 | -28.75 Mn |
| Apr 30, 2025 | -25.58 Mn |
| Jan 31, 2025 | -24.60 Mn |
| Oct 31, 2024 | -15.28 Mn |
| Jul 31, 2024 | -14.18 Mn |
| Apr 30, 2024 | -14.96 Mn |
| Jan 31, 2024 | -10.74 Mn |
| Oct 31, 2023 | -82.48 Mn |
| Jul 31, 2023 | -4.72 Mn |
| Apr 30, 2023 | -5.28 Mn |
| Jan 31, 2023 | -7.42 Mn |